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cute Coronary Syndromes Treated With
are-Metal and Drug-Eluting Stents
eville Kukreja, MA, Yoshinobu Onuma, MD, Hector M. Garcia-Garcia, MSC, MD,
oost Daemen, MD, Ron van Domburg, MD, PHD, Patrick W. Serruys, MD, PHD,
n behalf of the interventional cardiologists of the Thoraxcenter (2000 to 2005)
otterdam, the Netherlands
bjectives We aimed to evaluate the risk of deﬁnite stent thrombosis with bare-metal stents (BMS)
nd drug-eluting stents (DES) in patients treated for acute coronary syndromes.
ackground Acute coronary syndromes (ACS) have been reported as increasing the risk for stent
hrombosis.
ethods Between January 2000 and December 2005, 5,816 consecutive patients underwent percu-
aneous coronary intervention for de novo lesions with a single stent type. These patients consisted
f 3 sequential groups of BMS (n  2,248), sirolimus-eluting stents (n  822) and paclitaxel-eluting
tents (n  2,746). In total, 3,485 patients presented with an ACS.
esults After a median follow-up of 1,394 days, patients with ACS had a deﬁnite stent thrombosis
ate of 2.5% versus 1.0% in patients with stable angina (propensity score-adjusted hazard ratio [HR]:
.80, 95% conﬁdence interval [CI]: 1.72 to 4.56). ACS patients had a higher risk of early and late
tent thrombosis, although the increased risk of very late stent thrombosis was only present in ACS
atients treated with DES. In stable patients, any stent thrombosis resulted in a signiﬁcant increase
n mortality (adjusted HR: 4.0, 95% CI: 1.7 to 9.3), although this was particularly evident for late or
ery late stent thrombosis; in contrast only early stent thrombosis signiﬁcantly increased mortality in
atients with acute coronary syndrome patients (adjusted HR: 2.0, 95% CI: 1.0 to 4.1).
onclusions Patients with acute coronary syndromes are at higher risk of early and late stent
hrombosis with either BMS or DES, although very late stent thrombosis seems to be uniquely asso-
iated with DES. The clinical sequelae of late and very late stent thrombosis are more pronounced
n stable patients. (J Am Coll Cardiol Intv 2009;2:534–41) © 2009 by the American College of
ardiology Foundation
rom the Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.anuscript received August 28, 2008; revised manuscript received March 16, 2009, accepted April 6, 2009.
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535lthough dug-eluting stents (DES) reduce the rates of repeat
evascularization compared with bare-metal stents (BMS)
1–3), there remain concerns about the risk of late and very late
tent thrombosis (4–7). Many factors have been found to be
ssociated with the risk of stent thrombosis, including acute
oronary syndrome (ACS) at presentation (5,8–10). Mechan-
cal causes such as stent underexpansion, geographical miss,
nd edge dissections increase the risk of stent thrombosis in
oth BMS and DES (11–14). Delayed healing and impaired
eointimal strut coverage might increase this risk with DES
15–18). In patients with ACS, an additional particular poten-
ial problem is the trapping of thrombus between the stent
truts and vessel wall, which might contribute to late acquired
alapposition after thrombus resolution (14,19,20). Further-
ore, stenting of necrotic core-rich plaques might result in
tent strut penetration into the necrotic core with ensuing
issue prolapse and plaque disruption that might also contrib-
te to stent thrombosis (21). Nevertheless, a recent meta-
nalysis of patients with ST-segment elevation myocardial
nfarction (STEMI) found no difference in mortality between
ES and BMS after follow-up ranging between 12 and 24
onths, with significant reductions in repeat revascularization
ith DES (2). However, patients enrolled in randomized trials
re carefully selected and might represent only a small fraction
f those encountered in everyday clinical practice (22). There-
ore we investigated a consecutive series of all-comer patients
ndergoing percutaneous coronary intervention (PCI) with
MS and DES in our institution to evaluate the effect of
linical presentation on the occurrence of stent thrombosis.
ethods
etween January 2000 and December 2005, of 6,219
onsecutive patients undergoing PCI, 5,823 underwent PCI
or a de novo lesion with a single stent type (BMS,
irolimus-eluting stents [SES], or paclitaxel-eluting stents
PES]) as their standard treatment in our institution. The
nly exclusion criteria were the implantation of more than 1
ifferent stent type during the index procedure or PCI for
n-stent restenosis. Seven patients without clear documen-
ation of clinical presentation (4 treated with SES, 3 with
ES) were also excluded, leaving 5,816 patients whose data
ere analyzed.
Initially, all patients were treated with BMS, but on April
6, 2002, our institution adopted the use of SES (Cypher;
ordis, Warren, New Jersey) as the default strategy for all
oronary interventions. On February 16, 2003, SES was
eplaced by PES (Taxus; Boston Scientific, Natick, Massa-
husetts) as the default stent. Therefore this single-center
egistry consists of 3 sequential groups of consecutive
atients: BMS (n  2,248; January 2000 to April 2002),
ES (n  822; April 2000 to February 2003), and PES
n  2,746; February 2003 to December 2005). The
atients were also categorized according to clinical presen- oation as either stable angina (SA), unstable angina as
efined by the Braunwald (23) classification/non–ST-
egment elevation myocardial infarction (UA/NSTEMI), or
T-segment elevation myocardial infarction (STEMI).
cute coronary syndrome refers to either UA/NSTEMI or
TEMI (24,25).
All procedures were performed following standard pro-
edural guidelines at the time (26). The use of glycoprotein
b/3a inhibitors or adjunctive devices was left up to the
perator’s discretion. Angiographic success was defined as
esidual stenosis 30% by visual estimation in the presence
f Thrombolysis In Myocardial Infarction flow grade 3. All
atients were advised to maintain lifelong aspirin. Hyper-
holesterolemia was defined as fasting total cholesterol 5
mol/l (193 mg/dl) or the use of
ipid-lowering therapy. Hyper-
ension was defined as blood
ressure 140/90 mm Hg or
he use of antihypertensive med-
cations. Renal impairment was
efined as a serum creatinine
150 mol/l (1.7 mg/dl).
The primary end point was
tent thrombosis, defined as angio-
raphically documented thrombus
ith Thrombolysis In Myocardial
nfarction flow grade 0 or 1,
ccompanied by acute symptoms
consistent with the Academic
esearch Consortium classifica-
ion of definite stent thrombo-
is) (4,27). The timing of stent
hrombosis was categorized into
arly (within 30 days after im-
lantation), late (between 30
ays and 1 year), or very late
more than 1 year).
Secondary end points in-
luded all-cause mortality, any
yocardial infarction (MI), and
he composite of all-cause death or nonfatal MI. Myocardial
nfarction included re-infarction (defined as recurrence of
ymptoms together with ST-segment elevation or new left
undle branch block and an increase in cardiac enzymes
ollowing stable or decreasing values), or spontaneous MI
diagnosed by a rise in creatine kinase-myocardial band
raction of 3 times the upper limit of normal together with
ymptoms and either the development of ST-segment
levation or new left bundle branch block) (24).
Follow-up survival data for all patients were obtained
rom municipal civil registries. A questionnaire was subse-
uently sent to all living patients with specific enquiries
bout repeat hospital admission and adverse events. Because
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
HR  hazard ratio
IQR  interquartile range
MI  myocardial infarction
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SA  stable angina
SES  sirolimus-eluting
stent(s)
STEMI  ST-segment
elevation myocardial
infarction
UA  unstable anginaurs is the principal regional cardiac referral center, repeat
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536rocedures (percutaneous and surgical) are normally per-
ormed at our institution and recorded prospectively in our
atabase. For patients who suffered an adverse event at
nother center, medical records or discharge summaries
rom the other institutions were systematically reviewed.
eneral practitioners, referring cardiologists, and patients
ere contacted as necessary if further information was
equired. The protocol was approved by the hospital ethics
ommittee and is in accordance with the Declaration of
elsinki. Written informed consent was obtained from
very patient.
tatistical analysis. Categorical variables are presented as
ercentages and were compared by Pearson chi-square test
r Fisher exact test. Continuous variables are presented as
ean  SD and were compared by means of the indepen-
ent samples t test. A 2-sided p value of 0.05 was used to
ndicate statistical significance. The cumulative incidence of
dverse events was estimated according to the Kaplan-Meier
ethod, and curves were compared with the log-rank test.
atients lost to follow-up were considered at risk until the
ate of last contact, at which point they were censored.
eparate Cox multivariate regression analyses were per-
ormed for each paired clinical presentation comparison (SA
s. UA/NSTEMI, SA vs. STEMI, and UA/NSTEMI vs.
TEMI). To account for baseline differences in the DES
nd BMS cohorts, propensity scores were calculated by
ogistic regression with stent type (BMS, SES, or PES) and
ll significantly different pretreatment variables in Tables 1
nd 2 (28). The goodness-of-fit of the propensity score was
ssessed with the Hosmer-Lemeshow test, which suggested
hat the models used could explain the variance in depen-
ent variables (p  0.13). Clinical presentation and the
ropensity scores were then forced into separate forward
Table 1. Baseline Patient Characteristics
SA
BMS
(n  901)
DES
(n  1,369) p Value
BM
(n 
Male 71% 71% 0.9 68
Age (yrs) 62  11 63  11 0.2 63 
Hypertension 39% 50% 0.001 33
Hypercholesterolemia 53% 66% 0.001 43
Family history of CAD 23% 37% 0.001 22
Current smoker 21% 18% 0.06 22
Diabetes mellitus 14% 20% 0.001 15
Renal impairment 1% 3% 0.004 1
Previous myocardial
infarction
37% 32% 0.02 41
Previous CABG 15% 11% 0.001 12
Previous PCI 14% 13% 0.3 10
BMS bare-metal stent(s); CABG  coronary artery bypass grafting; CAD  coronary artery disea
ST-segment elevation myocardial infarction; UA/NSTEMI unstable angina or non–ST-segment eletepwise Cox multivariate regression analyses with the lariables in Tables 1 and 2 as in the preceding text.
ariables with a significance of p  0.1 were entered into
he next step. The final propensity score-adjusted results are
resented as adjusted hazard ratios (HRs) with 95% confi-
ence intervals. Further Cox multivariate analyses with stent
ype, clinical presentation, and all variables in Tables 1 and
were performed to identify independent predictors of stent
hrombosis. All statistical analyses were performed with
PSS for windows version 12.0.1 (SPSS, Inc., Chicago,
llinois).
esults
omplete follow-up was available for 97.6% of the patients.
he overall median follow-up duration was 1,394 days
interquartile range [IQR] 880 to 1,843). Patients with SA
r UA/NSTEMI had a significantly longer duration of
ollow-up than those with STEMI (p  0.001 for both
omparisons): stable median 1,470 days (IQR 958 to 1,930),
A/NSTEMI 1,493 days (IQR 967 to 2057), and STEMI
edian 1,187 (IQR 746 to 1,657). There were also signif-
cant differences (p  0.001) in the duration of follow-up
ccording to stent type: BMS median 2,120 days (IQR
,673 to 2,374) versus DES median 1,087 days (IQR 801 to
,454).
Baseline patient characteristics according to clinical pre-
entation and stent type are displayed in Table 1. Renal
mpairment and diabetes mellitus were more common in the
ES patients with SA and UA/NSTEMI compared with
heir BMS counterparts. Angiographic and procedural de-
ails are described in Table 2. Irrespective of clinical pre-
entation, DES patients had more stents implanted, with
UA/NSTEMI STEMI
DES
(n  1,010) p Value
BMS
(n  523)
DES
(n  1,189) p Value
68% 1.0 81% 77% 0.09
63  12 0.6 58  12 60  12 0.001
45% 0.001 21% 29% 0.001
58% 0.001 25% 31% 0.01
36% 0.001 21% 27% 0.04
25% 0.2 36% 40% 0.07
20% 0.001 10% 10% 0.9
3% 0.001 1% 1% 0.9
37% 0.07 20% 9% 0.001
10% 0.1 3% 2% 0.1
9% 0.8 4% 3% 0.3
 drug-eluting stent(s); PCI  percutaneous coronary intervention; SA  stable angina; STEMI 
myocardial infarction.S
824)
%
12
%
%
%
%
%
%
%
%
%
se; DESonger total stented lengths and smaller stent diameters than
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537he BMS cohort. The DES patients also underwent bifur-
ation treatment more frequently. Glycoprotein 2b/3a in-
ibitors were used less often in DES patients, although
lopidogrel was prescribed for longer.
The rates of definite stent thrombosis are presented in
able 3 and Figure 1. Stable patients had lower rates of
verall stent thrombosis than STEMI patients, UA/
STEMI, and overall ACS patients. After adjustment
or differences in baseline, angiographic, and procedural
haracteristics among patients with different clinical pre-
entations, both UA/NSTEMI and STEMI had signif-
cantly higher rates of any and early stent thrombosis than
table patients (Table 3). Late stent thrombosis was also
ore common in these 2 groups but did not reach
tatistical significance in the STEMI group. There was
lso a nonsignificant trend toward higher rates of very
Table 2. Angiographic and Procedural Details
SA
BMS
(n  901)
DES
(n  1,369) p Value (n
Number of diseased
vessels
1.8  0.8 1.8  0.8 0.2 1.
Number of vessels treated 1.4  0.6 1.4  0.6 0.3 1.
Number of lesions treated 1.8  1.0 1.8  1.0 0.6 1.
Number of stents
implanted
2.0  1.4 2.5  1.6 0.001 1.
Mean stent diameter (mm) 3.2  0.6 2.8  0.6 0.001 3.
Total implanted stent
length (mm)
30  23 49  35 0.001 2
Left main coronary artery
treated
4% 5% 0.1
Saphenous vein graft
treatment
5% 3% 0.03
Type B2 lesion 41% 4% 0.05
Type C lesion 39% 41% 0.4
Bifurcation 4% 16% 0.001
Intravascular ultrasound 25% 20% 0.003
Glycoprotein IIb/IIIa
inhibitor use
22% 12% 0.001
Angiographic success 95% 94% 0.09
Recommended duration of
clopidogrel (months)
3  2 6  4 0.001
Abbreviations as in Table 1.
Table 3. Rates of Stent Thrombosis After 3 Years According to Clinical Pre
Stent
Thrombosis
SA
(n  2,252)
UA/NSTEMI
(n  1,819)
STEMI
(n  1,666)
Any 1.0% 2.3% 2.8%
Early 0.5% 1.1% 1.4%
Late 0.2% 0.8% 0.5%
Very late 0.3% 0.4% 0.8%CI confidence interval; HR hazard ratio; other abbreviations as in Table 1.ate stent thrombosis in the UA/NSTEMI and STEMI
roups compared with SA. No significant differences
ould be found between the UA/NSTEMI and STEMI
roups.
When examining these groups according to stent type, we
ound that ACS patients had significantly higher rates of
verall stent thrombosis, whether treated with DES or
MS (Fig. 1C). Early and late stent thrombosis rates were
igher amongst ACS patients, although for DES this
ifference did not reach statistical significance. In the DES
atients, there was also a nonsignificant trend toward very
ate stent thrombosis (Fig. 2).
The mortality rates of patients with versus without stent
hrombosis were markedly higher for those with SA (Table
). Although mortality was also increased in both UA/
STEMI and STEMI patients with stent thrombosis, this
UA/NSTEMI STEMI
)
DES
(n  1,010) p Value
BMS
(n  523)
DES
(n  1,189) p Value
8 1.8  0.8 0.02 1.7  0.8 1.6  0.8 0.05
6 1.4  0.6 0.08 1.2  0.5 1.1  0.4 0.01
9 1.7  1.0 0.8 1.5  0.7 1.3  0.8 0.001
1 2.2  1.5 0.001 1.6  0.9 1.8  1.1 0.001
6 2.9  0.5 0.001 3.5  0.5 3.1  0.4 0.001
42  32 0.001 26  16 35  23 0.001
6% 0.01 4% 3% 0.8
5% 0.01 2% 1% 0.05
49% 0.003 40% 37% 0.1
35% 0.001 41% 47% 0.02
12% 0.001 3% 7% 0.001
18% 0.9 2% 6% 0.004
17% 0.001 48% 36% 0.001
97% 0.2 95% 97% 0.07
6  3 0.001 2  1 6  3 0.001
tion After Propensity Score Adjustment
/NSTEMI vs. SA
sted HR (95% CI)
STEMI vs. SA
Adjusted HR (95% CI)
UA/NSTEMI vs. STEMI
Adjusted HR (95% CI)
.58 (1.52–4.39) 3.10 (1.80–5.34) 0.83 (0.53–1.31)
.52 (1.16–5.49) 3.74 (1.74–8.05) 0.67 (0.35–1.29)
.18 (1.37–12.74) 2.13 (0.59–7.73) 1.96 (0.73–5.25)
.45 (0.52–4.00) 2.06 (0.79–5.35) 0.70 (0.28–1.74)BMS
 824
7  0.
3  0.
7  0.
8  1.
3  0.
8  18
3%
8%
56%
28%
4%
19%
33%
95%
2  2senta
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538as only apparent for those with early stent thrombosis,
hereas for SA patients, this finding applied regardless of
he timing of thrombosis.
Both types of ACS were independent predictors of overall
nd early stent thrombosis (Table 5). Unstable angina/
STEMI also predicted late stent thrombosis, whereas the
nly independent predictor of very late stent thrombosis was
Figure 1. Cumulative Incidence of Stent Thrombosis According to Clinical
and Stent Type
Kaplan-Meier estimates of deﬁnite stent thrombosis according to (A,B) clinical
syndromes; BMS  bare-metal stent(s); DES  drug-eluting stent(s); SA  stab
unstable angina or non–ST-segment elevation myocardial infarction.ES implantation. Discussion
ur results confirm the previous findings that presentation
ith ACS is a risk factor for stent thrombosis (5,8–10). We
ave found that this excessive risk occurs with both BMS
nd DES across all time points, with the exception of very
ate stent thrombosis, which seems to be a unique feature of
tation, in Stable and Unstable Patients, and According to Presentation
ntation and (C) clinical presentation and stent type. ACS  acute coronary
ina; STEMI  ST-segment elevation myocardial infarction; UA/NSTEMI Presen
prese
le angES implantation.
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539Although the low risk of stent thrombosis in stable
atients (overall 1% over 3 years in both BMS and DES) is
ncouraging, when it does occur, the consequences can be
evastating, with a 4-fold increase in mortality. Unstable
atients are at higher risk of stent thrombosis irrespective of
he stent type used, but the absolute increase in mortality
esulting from late or very late stent thrombosis seems to be
Figure 2. Classification of Stent Thrombosis Timing for All Patients, BMS,
Classiﬁcation of stent thrombosis timing for (A) all patients, (B) patients treate
tions as in Figure 1.
Table 4. Propensity Score-Adjusted Mortality Within 3 Years of the Index P
SA (n  2,252) Acut
Stent Thrombosis Mortality
Adjusted HR (95% CI) vs.
No Stent Thrombosis Morta
None 7% — 12%
Any 26% 4.0 (1.7–9.3) 14%
Early 17% 2.3 (0.6–9.5) 21%
Late 50% 4.9 (1.1–21.4) 9%
Very late 29% 7.3 (1.8–30.1) 5%Abbreviations as in Tables 1 and 3.ess than for stable patients. The mechanisms for this
henomenon are unclear, but the beneficial effects of isch-
mic preconditioning or the quality of any collateral vessels
ight provide some protection for unstable patients. It is
lso possible that patients with ACS might have tighter
ontrol of risk factors such as hypercholesterolemia, which
ight mitigate the potentially devastating effects of stent
ES
BMS, and (C) patients treated with DES. HR  hazard ratio; other abbrevia-
ure in Patients With and Without Definite Stent Thrombosis
nary Syndrome (n  3,485) Overall
Adjusted HR (95% CI) vs.
No Stent Thrombosis Mortality
Adjusted HR (95% CI) vs.
No Stent Thrombosis
— 10% —
1.5 (0.8–2.8) 16% 2.2 (1.3–3.6)
2.0 (1.0–4.1) 20% 2.5 (1.3–4.8)
0.9 (0.2–3.7) 15% 1.5 (0.6–4.2)
0.9 (0.1–6.6) 10% 2.5 (0.8–7.8)and D
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540hrombosis. Unfortunately, we do not have data on the
ontrol of risk-factors during follow-up and are therefore
nable to confirm or refute this hypothesis.
These findings highlight the importance of high-quality
nterventional techniques aimed at achieving optimal pro-
edural results irrespective of which stent type is implanted.
articularly, care should be taken to avoid potential me-
hanical factors including stent underexpansion, residual
dge dissections, and geographical miss of the target lesion.
he use of predilation and intravascular ultrasound might
ossibly help: a recent report of 12 patients with stent
hrombosis found that none of them achieved The MUSIC
Multicenter Ultrasound Stenting in Coronaries) criteria for
ptimal stent expansion (14,29). The use of thrombectomy
evices might also be beneficial, especially in those with a
arge thrombus burden (30,31).
Although current guidelines recommend 12 months of
ual antiplatelet therapy after DES implantation (32), the
uration of clopidogrel given to our patients was based upon
he protocols from the pivotal DES randomized controlled
rials (33,34); therefore initially patients treated with SES
ere routinely given 3 months clopidogrel, except for
omplex cases (bifurcations, multiple stents), who were
iven 6 months. All PES patients were routinely given 6
onths. Although the multivariable analysis adjusted for
he recommended duration of clopidogrel and this was not
ound to be an independent predictor of events, it is possible
hat the differences in dual antiplatelet therapy might have
ffected the results. We currently recommend, in line with
he most recent guidelines (32), dual antiplatelet therapy for
2 months after an ACS unless the patient is at high risk of
leeding and for 12 months after DES implantation.
Recent studies have evaluated the use of prasugrel, a new
hienopyridine, in place of clopidogrel. In patients with
CS, prasugrel reduced the rate of stent thrombosis from
.4% (similar to the rate in our ACS patients) to 1.1% (35).
he beneficial effect of prasugrel was found in patients
Table 5. Independent Predictors of Stent Thrombosis
Stent Thrombosis
Any STEMI
UA/NSTEMI
Number of stents implanted*
Early STEMI
UA/NSTEMI
Bifurcation treatment
Angiographic success
Late Saphenous vein graft treatment
UA/NSTEMI
Very late BMS use
*For each extra stent.
Abbreviations as in Tables 1 and 3.reated with BMS or DES (stent thrombosis HR: 0.36 for EES and HR: 0.52 for BMS) (36). However, major
leeding was more common in patients receiving prasugrel
2.4% vs.1.8%, HR: 1.32; 95% confidence interval: 1.03 to
.68; p  0.03). This included an increase in fatal bleeding
0.4% vs. 0.1%; p  0.002). Although patients with stent
hrombosis have higher mortality than those without stent
hrombosis, overall mortality in this report was no different
etween patients treated with prasugrel and those treated
ith clopidogrel. This suggests that the increase in bleeding
ith prasugrel might balance or even outweigh the small
bsolute excess risk of stent thrombosis in patients with
CS (1.5% over 3 years in our patients). Furthermore, any
ew antiplatelet regimen should demonstrate cost-
ffectiveness before it is widely accepted.
In summary, patients presenting with ACS are at higher
isk of early and late stent thrombosis with either BMS or
ES, although very late stent thrombosis seems to be
niquely associated with DES. There was little difference in
his aspect between STEMI and UA/NSTEMI. Stable
atients who suffered stent thrombosis had a 4-fold in-
reased risk of mortality.
tudy limitations. This is a single-center observational study.
urthermore, there are significant baseline and procedural
ifferences among the 3 historical stent groups, together with
ifferent lengths of follow-up due to their sequential nature.
evertheless, the use of a single stent type at any 1 time period
liminates bias toward using DES in higher-risk patients.
ecause many of our patients are transferred back to their
eferring hospital after PCI, we acknowledge that accurate data
egarding left ventricular function were not available and
herefore not included in the analysis.
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